PCSK9 Inhibitor Treatment Compliance of Patients with Coronary Heart Disease(CHD)Related Factors Analysis
Coronary atherosclerotic heart disease(CHD)causes a significant global health burden,among which the control of low-density lipoprotein cholesterol(LDL-C)level is a key treatment strategy.In recent years,inhibi-tors of pre protein converting enzyme Bacillus subtilis lysozyme 9(PCSK9)have become a first-line choice for the treatment of coronary heart disease due to their unique mechanism of action and ability to significantly reduce LDL-C.However,there are significant differences in patient adherence to PCSK9 inhibitors,which directly affects the clinical efficacy of the drugs.This study aims to comprehensively analyze various factors that affect the compliance of coronary heart disease patients with PCSK9 inhibitors,such as economic burden、patient education level、percep-tion of side effects、treatment expectations、drug coverage,etc.,through extensive database searches and literature reviews.It provides a comprehensive compliance improvement framework for clinical healthcare workers,aiming to improve treatment effectiveness and reduce the overall burden on coronary heart disease patients.
国家科技期刊平台
NSTL
万方数据
